The representative case reflecting the within-patient heterogeneity of Trop2 expression is presented in Figure 3D, showing different 68Ga-MY6349 uptake between the recurrent tumor (negative Trop2 expression, SUVmax 1.7) and metastatic lung lesions (positive Trop2 expression, SUVmax 13.7) in a patient with metastatic thyroid cancer. Here, TACSTD2 is linked to neoplasm.